Abstract: A solvent that reversibly converts from a nonionic liquid mixture to an ionic liquid upon contact with a selected trigger, e.g., contact with CO2, is described. In preferred embodiments, the ionic solvent is readily converted back to the nonionic liquid mixture. The nonionic liquid mixture includes an amidine or guanidine or both, and water, alcohol, or a combination thereof. Single component amine solvents that reversibly convert between ionic and non-ionic states are also described. Some embodiments require increased pressure to convert; others convert at 1 atmosphere.

Abstract: The present invention relates to methods and formulations for inhibiting, treating and preventing a malignant cell phenotype, cell, tumor and/or disease. Administration of nitric oxide mimetics, such as low doses, is sufficient to increase, restore or maintain nitric oxide-mediated signaling in cells so that malignant cell phenotypes, cells, tumors and/or diseases are inhibited or prevented. These methods and formulations are particularly useful in treating and preventing cancer in animals.

Abstract: Embodiments of the invention provide a method of using Schwartz Reagent, Cp2Zr(H)Cl, without accumulating or isolating it. Methods provide mixtures of Cp2ZrCl2, reductants that selectively reduce Cp2ZrCl2, and substrates. After reaction of Cp2ZrCl2 and the reductant, an intermediate reduction product is formed, apparently Schwartz Reagent. The in situ Schwartz Reagent then selectively reduces certain functional groups on the substrate. Substrates include tertiary amides, tertiary benzamides, aryl O-carbamates, and heteroaryl N-carbamates, which are reduced to aldehydes, benzaldehydes, aromatic alcohols, and heteroaromatics, respectively. Compared to prior methods, reagents are inexpensive and stable, reaction times are short, and reaction temperature in certain cases is conveniently room temperature. It has been estimated that using the in situ method described herein instead of synthesized or commercially obtained Schwartz Reagent provides a 50% reduction in cost.

Abstract: A cast aluminum alloy containing up to about 0.35% by weight chromium is heated to a first elevated temperature to homogenize the casting and dissolve the chromium content in an aluminum-based matrix phase. The alloy is then heated at a lower elevated temperature to cause the precipitation of a portion of the chromium as an aluminum-containing and chromium-containing intermetallic compound. A suitable amount of chromium is retained in solid solution in aluminum. Thus, the concentration of dissolved chromium in an aluminum alloy may be controlled to fall within specified ranges which result in improvements in both the strength and ductility of the alloy. Impurity amounts of iron may also be precipitated as intermetallic particles from the aluminum matrix to enhance the ductility of the aluminum-based alloy.

Abstract: This invention relates to gaze tracking methods and systems integrated with virtual reality (VR) or augmented reality (AR). A system may include one or more cameras for capturing images of a subject's eyes, a display device for displaying a VR or AR image, a first reflecting surface associated with the display device for at least partially reflecting light from the eyes to the one or more cameras and for transmitting the VR or AR image; and a second reflecting surface for at least partially reflecting light from the eyes to the one or more cameras and for receiving the VR or AR image and rendering the VR or AR image to the subject as at least one component of a VR or AR environment. The methods and systems described herein may be used in research, medical, industrial, aerospace, and entertainment applications.

Abstract: A hybrid nanotube, high-performance, dynamically reconfigurable architecture, NATURE, is provided, and a design optimization flow method and system, NanoMap. A run-time reconfigurable architecture is provided by associating a non-volatile universal memory to each logic element to enable cycle-by-cycle reconfiguration and logic folding, while remaining CMOS compatible. Through logic folding, significant logic density improvement and flexibility in performing area-delay tradeoffs are possible. NanoMap incorporates temporal logic folding during the logic mapping, temporal clustering and placement steps. NanoMap provides for automatic selection of a best folding level, and uses force-direct scheduling to balance resources across folding stages. Mapping can thereby target various optimization objectives and user constraints.

Abstract: Disclosed are compounds of the general formula (I): compositions comprising an effective amount of said compounds either alone or in combination with other chemotherapeutic agents, and methods useful for treating or preventing cancer and for inhibiting tumour tissue growth. These compounds attenuate the oxidative damage associated with increased heme-oxygenase activity and can reduce cell proliferation in transformed cells. In addition, the described compounds and compositions are useful as neuroprotectants and for treating or preventing neurodegenerative disorders and other diseases of the central nervous system.

Abstract: This invention relates to methods and apparatus for improving communications between humans and devices. The invention provides a method of modulating operation of a device, comprising: providing an attentive user interface for obtaining information about an attentive state of a user; and modulating operation of a device on the basis of the obtained information, wherein the operation that is modulated is initiated by the device. Preferably, the information about the user's attentive state is eye contact of the user with the device that is sensed by the attentive user interface.

Abstract: Disclosed are compounds of the general formula (I): T?C?nD??(I), compositions comprising an effective amount of said compounds either alone or in combination with other chemotherapeutic agents, and methods useful for treating or preventing cancer and for inhibiting tumour tissue growth. These compounds attenuate the oxidative damage associated with increased heme-oxygenase activity and can reduce cell proliferation in transformed cells. In addition, the described compounds and compositions are useful as neuroprotectants and for treating or preventing neurodegenerative disorders and other diseases of the central nervous system.

Abstract: Provided is a current-source gate driver for use with a switching device having a gate capacitance, including an input terminal for receiving a DC voltage; a first switch connected between the input terminal and an output terminal; a second switch connected between the output terminal and a circuit common; a series circuit comprising a first capacitor and an inductor, the series circuit connected between the input terminal and the output terminal; wherein the gate capacitance of the switching device is connected between the output terminal and the circuit common. The current-source gate driver improves efficiency of the power switching devices of a voltage regulator module or other switching converter.

Abstract: This invention relates to a spinal facet cap for treating scoliosis, the facet cap comprising a shim portion for inserting into a facet joint of a spine, and an alignment portion for maintaining alignment of the shim portion within the facet joint. The invention also provides a method for treating scoliosis, comprising implanting at least one spinal facet cap into at least one facet joint of a subject in need thereof.

Abstract: Peptides and mimetics of selected domains of mammalian serum amyloid A isoform 2.1 (SAA2.1) and compounds and compositions thereof are provided that enhance the effect on macrophage cholesterol ester hydrolase activity and/or inhibit acyl CoA:cholesterol acyl transferase activity. Methods of using these compositions in the treatment and/or prevention of atherosclerosis as well as coronary heart disease and cardiovascular disease are also provided.

Abstract: A multi-module bidirectional power converter may comprise a low side common node, a high side common node and at least first and second bidirectional DC/DC converter modules. The modules may comprise first and second low voltage switches, first and second high voltage switches and a transformer. The transformer may comprise a low side winding having first and second legs and a high side winding having first and second legs. The first leg of the low side winding may be connected with the first and second low voltage switches of the module. The second leg of the low side winding may be connected with the low side common node of the multi-module bidirectional power converter. The first leg of the high side winding may be connected with the first and second high voltage switches of the module. The second leg of the high side winding may be connected to the high side common node of the multi-module bidirectional power converter.

Abstract: The invention relates to a tool comprising a handle and a tip, which provides amplified tactile feedback to a user regarding the material with which the tip of the tool is in contact. In one embodiment, tactile feedback is provided to the user via the handle of the tool, in the form of movements which correspond at least partially to those experienced by the tip of the tool as it interacts with the material. The tool optionally provides audio and/or visual feedback regarding the material. In a preferred embodiment, the tool is a surgical instrument.

Abstract: A method of predicting a clinical outcome for a patient with congestive heart failure is disclosed. A plurality of nonlinear first PCI models are identified based on a biomarker dataset, each of the models having a number of distinct terms. One or more second PCI models are identified based on the biomarker dataset, each of these models having a number of distinct terms which corresponds to the number of distinct terms for one or more of the nonlinear first PCI models. Each of the plurality of nonlinear first PCI models are statistically compared to one of the one or more second PCI models having a corresponding number of distinct terms to determine a preference for higher versus lower degree of nonlinearity or preference for shorter versus longer memory length. The clinical outcome is predicted based on the preference for higher versus lower degree of nonlinearity or memory length preference.

Abstract: A solvent that reversibly converts from a nonionic liquid mixture to an ionic liquid upon contact with a selected trigger, e.g., contact with CO2, is described. In preferred embodiments, the ionic solvent is readily converted back to the nonionic liquid mixture. The nonionic liquid mixture includes an amidine or guanidine or both, and water, alcohol, or a combination thereof. Single component amine solvents that reversibly convert between ionic and non-ionic states are also described. Some embodiments require increased pressure to convert; others convert at 1 atmosphere.

Abstract: A method and apparatus for eye gaze tracking in human or animal subjects without calibration of cameras, specific measurements of eye geometries, or tracking of a cursor image on a screen by the subject through a known trajectory. One embodiment provides a method for tracking a user's eye gaze at a surface, object, or visual scene, comprising: providing an imaging device for acquiring images of at least one of the user's eves: modeling, measuring, estimating, and/or calibrating for the user's head position: providing one or more markers associated with the surface, object, or visual scene for producing corresponding glints or reflections in the user's eyes; analyzing the images to find said glints or reflections and/or the pupil: and determining eye gaze of the user upon a said one or more marker as indicative of the user's eye gaze at the surface, object, or visual scene.

Abstract: Disclosed in certain embodiments is a method of treating and/or mitigating prostate cancer, ovarian cancer, melanoma, colorectal cancer, breast cancer or lung cancer, comprising administering to an individual in need thereof a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula (I): where T is optionally substituted phenyl; n is 1 to 6: C represents optionally substituted carbon; and D is imidazolyl; or a pharmaceutically acceptable salt or ester of said compound.

Abstract: The invention provides a method and apparatus for measuring one or more optical properties, such as absorbance and refractive index, of a test medium such as a gas, a liquid, or solid material. The method comprises providing a passive optical waveguide loop comprising the test medium, launching in the optical loop an intensity-modulated light at a reference phase, detecting a phase of said light along the optical waveguide loop, and comparing the detected phase of said light along the loop with the reference phase, wherein the comparison provides information about one or more optical properties of the test medium.

Abstract: The present invention relates to methods and formulations for inhibiting, treating and preventing a malignant cell phenotype, cell, tumor and/or disease. Administration of nitric oxide mimetics, such as low doses, is sufficient to increase, restore or maintain nitric oxide-mediated signaling in cells so that malignant cell phenotypes, cells, tumors and/or diseases are inhibited or prevented. These methods and formulations are particularly useful in treating and preventing cancer in animals.